AI주식인사이트AI Stock Insight
B

엔케이젠바이오텍코리아

182400KOSDAQ기초 의약물질 제조업

55.3 / 100

Reference Date: 2026-07-24

Financial Score14.0 / 40
News Sentiment21.3 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Enkmax BioTech Korea focuses on immunotherapy, immunodiagnostic kits, health supplement sales, and bio research reagents. The company utilizes its 'SuperNK' platform technology, based on NK cells, to develop immunotherapy treatments for various diseases, with global clinical trials underway. Its immunodiagnostic kits, the world's first to measure NK cell activity in whole blood, hold patents in 30 countries, and health supplements like NK365, which enhance immunity, are also a key product line.

Number of Employees

70people

Average Salary

0.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 25.444.0Point
PBR
—Industry Average 1.263.5Point
ROE
—Industry Average -6.033.5Point
Debt Ratio
57.01Industry Average 6.620.0Point

8.6x industry avg (risky)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼11.1% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲65.8% (2-year basis)

ROE Trend
0.0 / 4

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position4.0Point

52w mid range (50%)

Current 3,670Won52-week high 3,67052-week low 3,670
1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0